C4 Therapeutics, Inc.
C4 Therapeutics, Inc.（CCCC）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CCCC · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
1
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
C4 Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
CCCC 季度内部人买卖趋势
CCCC 内幕交易卖出 · CCCC 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · CCCC CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CCCC 高管卖出股份 · CCCC 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Anderson Kenneth Carl Director | Option | 1,070 | $2K | Form 4 |
| Apr 1, 2026 | Anderson Kenneth Carl Director | Award | 4,259 | $11K | Form 4 |
| Apr 1, 2026 | GROGAN DONNA ROY Director | Award | 5,370 | $14K | Form 4 |
| Feb 13, 2026 | Boyle Scott N Chief Business Officer | Award | 200,000 | — | Form 4 |
| Feb 13, 2026 | Boyle Scott N Chief Business Officer | Option | 5,000 | — | Form 4 |
| Feb 14, 2026 | Boyle Scott N Chief Business Officer | Option | 20,950 | — | Form 4 |
| Feb 13, 2026 | Boyle Scott N Chief Business Officer | Other | 1,735 | $3K | Form 4 |
| Feb 14, 2026 | Boyle Scott N Chief Business Officer | Other | 7,269 | $14K | Form 4 |
| Feb 13, 2026 | Mahaney Paige Chief Scientific Officer | Award | 240,000 | — | Form 4 |
| Feb 14, 2026 | Mahaney Paige Chief Scientific Officer | Option | 7,050 | — | Form 4 |
| Feb 14, 2026 | Mahaney Paige Chief Scientific Officer | Other | 2,446 | $5K | Form 4 |
| Feb 13, 2026 | Schick Kelly CPO | Award | 200,000 | — | Form 4 |
| Feb 13, 2026 | Schick Kelly CPO | Option | 5,000 | — | Form 4 |
| Feb 14, 2026 | Schick Kelly CPO | Option | 20,950 | — | Form 4 |
| Feb 13, 2026 | Schick Kelly CPO | Other | 1,735 | $3K | Form 4 |
| Feb 14, 2026 | Schick Kelly CPO | Other | 7,269 | $14K | Form 4 |
| Feb 14, 2026 | Hirsch Andrew President & CEO · Director | Option | 81,725 | — | Form 4 |
| Feb 13, 2026 | Hirsch Andrew President & CEO · Director | Award | 700,000 | — | Form 4 |
| Feb 14, 2026 | Hirsch Andrew President & CEO · Director | Other | 39,154 | $74K | Form 4 |
| Feb 15, 2026 | Hirsch Andrew President & CEO · Director | Option | 20,400 | — | Form 4 |
| Feb 15, 2026 | Hirsch Andrew President & CEO · Director | Other | 9,057 | $17K | Form 4 |
| Feb 13, 2026 | REYNO LEONARD Chief Medical Officer | Award | 240,000 | — | Form 4 |
| Feb 14, 2026 | REYNO LEONARD Chief Medical Officer | Option | 30,950 | — | Form 4 |
| Feb 14, 2026 | REYNO LEONARD Chief Medical Officer | Other | 16,579 | $31K | Form 4 |
| Feb 13, 2026 | Adams Kendra CFO | Award | 240,000 | — | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CCCC 内幕交易
CCCC 内幕交易
C4 Therapeutics, Inc.（CCCC）内幕交易数据来源于公司内部人（包括Adams Kendra (CFO), Anderson Kenneth Carl (Director), Boyle Scott N (Chief Business Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。CCCC内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看C4 Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CCCC 内幕交易 · 5个问题C4 Therapeutics, Inc.（CCCC）的内部人包括高管和董事，如Adams Kendra (CFO), Anderson Kenneth Carl (Director), Boyle Scott N (Chief Business Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026